J&J CFO Wolk Said Company Does Not Have Scientific Expertise To Get Into Obesity Drug Development At The Moment
Portfolio Pulse from Charles Gross
In an interview cited by Reuters, J&J's CFO Wolk stated that the company currently lacks the scientific expertise to venture into obesity drug development.
October 17, 2023 | 11:54 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
J&J's inability to develop obesity drugs may limit its growth opportunities in the pharmaceutical sector.
Obesity is a growing health concern worldwide, and companies that can develop effective treatments stand to benefit significantly. J&J's inability to develop such drugs could limit its growth opportunities in this lucrative market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
J&J's lack of expertise in obesity drug development could potentially benefit competitors like Novo Nordisk, which has a strong presence in this market.
With J&J not venturing into obesity drug development, competitors like Novo Nordisk, which already has a strong presence in this market, could potentially benefit from less competition.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50